Merck Secures $700 Million from Blackstone to Accelerate Development of Next-Generation TROP2 ADC, Sacituzumab Tirumotecan

A significant financial collaboration has been finalized to dramatically accelerate the clinical development of sacituzumab tirumotecan (sac-TMT), a highly promising, next-generation antibody-drug conjugate (ADC) designed to combat a wide spectrum of aggressive and difficult-to-treat solid tumors.

Through this new and innovative research and development funding agreement, Merck (known as MSD outside the United States and Canada) will receive $700 million from Blackstone Life Sciences. This substantial non-dilutive capital infusion is earmarked to support the ongoing late-stage clinical development of sac-TMT, specifically by covering a portion of the extensive Phase 3 costs expected to occur through 2026.

The Science Behind Sac-TMT: A Highly Targeted Therapy

Sac-TMT is an experimental therapy that represents a major advancement in targeted cancer treatment. It has been meticulously engineered to target the TROP2 protein, which is found to be highly expressed across numerous solid tumor types, including aggressive forms of breast, endometrial, and lung cancers.

The drug is an Antibody-Drug Conjugate, a class of therapy that functions as a “guided missile” to deliver chemotherapy directly to cancer cells. Sac-TMT’s structure is defined by three key components:

TROP2-Targeting Antibody: This component precisely identifies and binds to the TROP2 protein on the tumor cell surface.
Potent Topoisomerase-1 Inhibitor Payload: This is the powerful, cancer-killing chemotherapy agent.
Innovative Linker Technology: This crucial technology connects the antibody and the payload. It is designed to provide a high drug-to-antibody ratio, enabling the precise and concentrated delivery of the cancer-killing compound directly into the tumor cells, thereby maximizing efficacy while simultaneously minimizing damage to surrounding healthy tissues.

Extensive Clinical Program Underway

Merck’s strong conviction in the therapeutic potential of sac-TMT is evidenced by the robust clinical program currently in motion. The drug is currently being evaluated in an expansive program involving 15 separate Phase 3 trials across six different tumor types, positioning it as a potentially foundational treatment across oncology.

Terms of the Strategic Partnership

Under the detailed terms of the agreement, Merck retains full operational control over the entire lifecycle of sac-TMT, encompassing its development, manufacturing, and global commercialization efforts.

Blackstone Life Sciences’ role is solely limited to providing financial backing. In exchange for the $700 million investment, which serves to share the significant financial risk associated with large-scale clinical trials and accelerate the drug’s progress, Blackstone will receive low- to mid-single-digit royalties on the drug’s global net sales. This royalty is contingent upon sac-TMT gaining regulatory approval in Merck’s marketing territories and achieving U.S. regulatory approval for the first-line treatment of triple-negative breast cancer.

A Growing Trend in Biopharma Funding

This financing structure highlights an increasingly prevalent model within the biopharmaceutical industry. Such strategic funding partnerships enable companies like Merck to access substantial, non-dilutive capital to fast-track innovative therapies through critical clinical stages while fully maintaining scientific and operational independence and ownership of the underlying intellectual property.

If clinical development proves successful and regulatory approval is granted, sac-TMT has the potential to become a major, life-changing advancement in targeted cancer therapy, offering renewed hope to patients struggling against aggressive and treatment-resistant forms of cancer globally. The partnership between Merck and Blackstone demonstrates the powerful synergy created by combining world-class scientific leadership with strategic financial investment to effectively tackle some of the world’s most daunting health challenges.